GlobeNewswire·May 11, 2026, 4:15 PM ET

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

CG Oncology will present first results from the CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy for High-Risk BCG-Exposed & BCG-Unresponsive patients at the AUA 2026 Annual Meeting in Washington, D.C.
The Phase 2 study title is "Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive Non-Muscle Invasive Bladder Cancer."
A poster presentation on the CORE-008 data is scheduled for May 15, 2026, from 3:30–5:30 PM ET, followed by a podium presentation at the SUO 2026 Annual Meeting on May 16, 2026, from 4:25–4:30 PM ET.
Grant recipients of the CG-SUO-CTC NMIBC Research Fellowship will present research on spatial transcriptomic profiling & dynamic intra-tumor heterogeneity in BCG-Unresponsive NMIBC patients on May 16.
CG Oncology will exhibit at booth #3051 to showcase its clinical development program & commitment to bladder cancer therapies.
CG Oncology is a late-stage clinical biopharmaceutical company developing a potential backbone bladder-sparing therapeutic for urologic cancer patients.